Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGPhase 2INTERVENTIONAL

Desloratadine in Patients With Ulcerative Colitis

Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.

Who May Be Eligible (Plain English)

Who May Qualify: - Both male and female sex. - patients with age ranged from 18 to 65. - patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline. - Patients treated with 5-aminosalisylic acid (mesalamine). Who Should NOT Join This Trial: - Patients with severe UC - Significant liver or kidney function abnormalities - Pregnant or lactating females - Treatment with systemic or rectal steroids - Treatment with immunosuppressant or biological therapies - Known allergy to desloratadine or any ingredient in the formulation - Patients with other inflammatory diseases - Patients with history of colon cancer - Patients with complete or partial colectomy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Both male and female sex. * patients with age ranged from 18 to 65. * patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline. * Patients treated with 5-aminosalisylic acid (mesalamine). Exclusion Criteria: * Patients with severe UC * Significant liver or kidney function abnormalities * Pregnant or lactating females * Treatment with systemic or rectal steroids * Treatment with immunosuppressant or biological therapies * Known allergy to desloratadine or any ingredient in the formulation * Patients with other inflammatory diseases * Patients with history of colon cancer * Patients with complete or partial colectomy

Treatments Being Tested

DRUG

Desloratadine

mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months.

DRUG

mesalamine

mesalamine 1000 mg three times daily for 3 months

Locations (1)

Menofia university Hospitals
Shibīn al Kawm, Menofia, Egypt